← Back to Clinical Trials
Recruiting NCT05787795

NCT05787795 Identifying and Characterizing Preclinical MS

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05787795
Status Recruiting
Phase
Sponsor Yale University
Condition Multiple Sclerosis
Study Type OBSERVATIONAL
Enrollment 1,000 participants
Start Date 2022-06-21
Primary Completion 2032-06-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
biological samples

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 1,000 participants in total. It began in 2022-06-21 with a primary completion date of 2032-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this research study is to try and identify risk factors and biologic changes that suggest that someone may go on to develop multiple sclerosis before a person has shown any symptoms of the disease.

Eligibility Criteria

Inclusion Criteria: * Age 18+ * Having one or more risk factors for multiple sclerosis, including one or more of the below: * Individuals known to have a radiologically isolated syndrome * Individuals with a family history of multiple sclerosis (first degree family member) * Individuals with personal risk factors, which are known to include smoking, obesity, Epstein Barr virus infections, Vitamin D deficiency, genetic risk score Exclusion Criteria: * Currently pregnant * Diagnosis of multiple sclerosis or any ongoing, systemic autoimmune disease * Ongoing treatment with immunosuppressive medications

Contact & Investigator

Central Contact

Erin Longbrake, MD

✉ erin.longbrake@yale.edu

📞 860-287-6100

Principal Investigator

Erin Longbrake, MD

PRINCIPAL INVESTIGATOR

Yale University

Frequently Asked Questions

Who can join the NCT05787795 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Sclerosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05787795 currently recruiting?

Yes, NCT05787795 is actively recruiting participants. Contact the research team at erin.longbrake@yale.edu for enrollment information.

Where is the NCT05787795 trial being conducted?

This trial is being conducted at North Haven, United States.

Who is sponsoring the NCT05787795 clinical trial?

NCT05787795 is sponsored by Yale University. The principal investigator is Erin Longbrake, MD at Yale University. The trial plans to enroll 1,000 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology